Type 2 Diabetes Mellitus Clinical Trial
Official title:
The Long-term Effects of an Intensive Lifestyle Intervention for Type 2 Diabetes on Medicare Eligibility, Health Care Use, and Health Care Spending
NCT number | NCT03952728 |
Other study ID # | UP-16-00706 |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | December 19, 2016 |
Est. completion date | June 30, 2022 |
Verified date | September 2022 |
Source | University of Minnesota |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
This study investigates whether an intensive lifestyle intervention for type 2 diabetes had long-term effects on Medicare enrollment, health care use, and health care spending.
Status | Completed |
Enrollment | 2796 |
Est. completion date | June 30, 2022 |
Est. primary completion date | June 30, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 45 Years to 75 Years |
Eligibility | Inclusion Criteria: - Look AHEAD participation: met age requirements and other criteria at time of study enrollment (as noted in Look AHEAD Research Group (2013)) - Consented to administrative data linkages - Provided individual identifiers that could be linked with Medicare databases - Were successfully linked to Medicare data Exclusion Criteria: - |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
University of Minnesota | University of Southern California, Wake Forest University |
Huckfeldt PJ, Frenier C, Pajewski NM, Espeland M, Peters A, Casanova R, Pi-Sunyer X, Cheskin L, Goldman DP. Associations of Intensive Lifestyle Intervention in Type 2 Diabetes With Health Care Use, Spending, and Disability: An Ancillary Study of the Look — View Citation
Look AHEAD Research Group, Wing RR, Bolin P, Brancati FL, Bray GA, Clark JM, Coday M, Crow RS, Curtis JM, Egan CM, Espeland MA, Evans M, Foreyt JP, Ghazarian S, Gregg EW, Harrison B, Hazuda HP, Hill JO, Horton ES, Hubbard VS, Jakicic JM, Jeffery RW, Johnson KC, Kahn SE, Kitabchi AE, Knowler WC, Lewis CE, Maschak-Carey BJ, Montez MG, Murillo A, Nathan DM, Patricio J, Peters A, Pi-Sunyer X, Pownall H, Reboussin D, Regensteiner JG, Rickman AD, Ryan DH, Safford M, Wadden TA, Wagenknecht LE, West DS, Williamson DF, Yanovski SZ. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med. 2013 Jul 11;369(2):145-54. doi: 10.1056/NEJMoa1212914. Epub 2013 Jun 24. Erratum in: N Engl J Med. 2014 May 8;370(19):1866. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Originally eligible for Medicare through Old Age and Survivor's Insurance | This is based on "Original Reason for Entitlement" field in Medicare Beneficiary Summary File | 12-years | |
Other | Originally eligible for Medicare through Disability Insurance Benefits | This is based on "Original Reason for Entitlement" field in Medicare Beneficiary Summary File | 12-years | |
Other | Originally eligible for Medicare due to End Stage Renal Disease (ESRD) | This is based on "Original Reason for Entitlement" field in Medicare Beneficiary Summary File | 12-years | |
Other | Hospital readmissions | Based on HEDIS specifications | 12-years | |
Other | Inpatient medicine discharges | Based on patient-level HEDIS specifications | 12-years | |
Other | Inpatient surgical discharges | Based on patient-level HEDIS specifications | 12-years | |
Other | Inpatient medicine days | Based on patient-level HEDIS specifications | 12-years | |
Other | Inpatient surgical days | Based on patient-level HEDIS specifications | 12-years | |
Other | Medicare Dialysis Payments | Based on Medicare records | 12-years | |
Other | Medicare Durable Medical Equipment payments | Based on Medicare records | 12-years | |
Other | Medicare Imaging + Test payments | Based on Medicare records | 12-years | |
Primary | Total inpatient (general hospital/acute care) discharges | This is based on patient-level HEDIS specifications. | 12-years | |
Primary | Total inpatient (general hospital/acute care) days | This is based on patient-level HEDIS specifications. | 12-years | |
Primary | Total number of emergency department visits | This is based on patient-level HEDIS specifications. | 12-years | |
Primary | Medicare Part D Prescription Drug Fill Count | Derived measure indicating number of 30-day supply equivalents in each year. | 12-years | |
Secondary | Total Medicare spending | Sums Medicare payments across service use categories | 12-years | |
Secondary | Medicare inpatient payments | Patient-level inpatient payments | 12-years | |
Secondary | Medicare Part D drug payments | Part D plan payments for covered drugs in a given year | 12-years | |
Secondary | Medicare Part D drug costs | Gross drug costs for all Part D drugs for a given year | 12-years | |
Secondary | Medicare outpatient visits | Based on patient-level HEDIS specifications | 12-years | |
Secondary | Medicare hospital outpatient payments | Based on Medicare records | 12-years | |
Secondary | Medicare Part B physician payments | Based on Medicare records | 12-years | |
Secondary | Medicare Skilled Nursing Facility payments | Based on Medicare records | 12-years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02771093 -
An Exploratory Study of the Effects of Trelagliptin and Alogliptin on Glucose Variability in Patients With Type 2 Diabetes Mellitus
|
Phase 4 | |
Completed |
NCT02545842 -
Assessment Study of Three Different Fasting Plasma Glucose Targets in Chinese Patients With Type 2 Diabetes Mellitus (BEYOND III/FPG GOAL)
|
Phase 4 | |
Recruiting |
NCT03436212 -
Real-Life Home Glucose Monitoring Over 14 Days in T2D Patients With Intensified Therapy Using Insulin Pump.
|
N/A | |
Completed |
NCT03244800 -
A Study to Investigate Different Doses of 0382 in Overweight and Obese Subjects With Type 2 Diabetes Mellitus.
|
Phase 2 | |
Completed |
NCT03960424 -
Diabetes Management Program for Hispanic/Latino
|
N/A | |
Withdrawn |
NCT02769091 -
A Study in Adult Patients With Nonalcoholic Steatohepatitis Who Also Have Type 2 Diabetes
|
Phase 2 | |
Recruiting |
NCT06065540 -
A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor
|
Phase 3 | |
Recruiting |
NCT05008276 -
Puberty, Diabetes, and the Kidneys, When Eustress Becomes Distress (PANTHER Study)
|
||
Completed |
NCT04091373 -
A Study Investigating the Pharmacokinetics of a Single Dose Administration of Cotadutide
|
Phase 1 | |
Completed |
NCT03296800 -
Study to Evaluate Effects of Probenecid, Rifampin and Verapamil on Bexagliflozin in Healthy Subjects
|
Phase 1 | |
Recruiting |
NCT06212778 -
Relationship Between Nutritional Status, Hand Grip Strength, and Fatigue in Hospitalized Older Adults With Type 2 Diabetes Mellitus.
|
||
Completed |
NCT05979519 -
Fresh Carts for Mom's to Improve Food Security and Glucose Management
|
N/A | |
Recruiting |
NCT05579314 -
XW014 in Healthy Subjects and Patients With Type 2 Diabetes Mellitus (T2DM)
|
Phase 1 | |
Completed |
NCT03859934 -
Metabolic Effects of Melatonin Treatment
|
Phase 1 | |
Terminated |
NCT03684642 -
Efficacy and Safety of Efpeglenatide Versus Dulaglutide in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin
|
Phase 3 | |
Completed |
NCT03248401 -
Effect of Cilostazol on Carotid Atherosclerosis Estimated by 3D Ultrasound in Patients With Type 2 Diabetes
|
Phase 4 | |
Completed |
NCT03644134 -
A Personalized Intervention to Manage Physiological Stress and Improve Sleep Patterns
|
N/A | |
Completed |
NCT05295160 -
Fasting-Associated Immune-metabolic Remission of Diabetes
|
N/A | |
Completed |
NCT02836873 -
Safety and Efficacy of Bexagliflozin in Type 2 Diabetes Mellitus Patients With Moderate Renal Impairment
|
Phase 3 | |
Completed |
NCT02226003 -
Efficacy and Safety of Ertugliflozin (MK-8835/PF-04971729) With Sitagliptin in the Treatment of Participants With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Diet and Exercise (MK-8835-017)
|
Phase 3 |